Overview

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

National Institute on Aging (NIA)

Treatments:

Quinacrine